PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will be raising C$10.0 million via a financing conducted exclusively by H.C. Wainwright.

The financing will see the company sell a total of 15.6 million units of the company price at $0.64 per each, with each unit containing one common share and one common share purchase warrant. Each warrant, priced at $0.80 per share, is valid for a period of five years from the date of issuance.

Proceeds from the financing are to be used for the development of the firms microneedle patch, its ketamine product, and general working capital.

The financing is currently slated to close September 28, 2021.

PharmaTher Holdings last traded at $0.80 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. PharmaTher Holdings is a former client of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Silver @ $36 & We’re Still 200M Oz Short | Paul Andre Huet – Americas Gold and Silver

Gold’s Wild Bull Run: Are Markets About to Break? | Mike McGlone

First Majestic Silver: The Santa Elena Mine

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

PharmaTher Submits For Phase 2 Clinical Trial With FDA

PharmaTher Holdings (CSE: PHRM) is looked to complete a phase two clinical trial. The company...

Tuesday, April 20, 2021, 07:38:21 AM

PharmaTher Receives FDA Approval For Ketamine Trial For Parkinson’s

PharmaTher Holdings (CSE: PHRM) has seen the US FDA approve the firms application for an...

Monday, May 17, 2021, 09:15:31 AM

Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli

Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down...

Tuesday, November 24, 2020, 01:00:00 PM

PharmaTher Collaborates For Research On Psychedelic Microdosing Tech

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related...

Tuesday, February 23, 2021, 07:25:33 AM

Pharmather Files For Orphan Drug Status For Use Of Ketamine Against Postherpetic Neuralgia

Pharmather Inc (CSE: PHRM) this morning announced that it has filed for orphan drug status...

Tuesday, October 27, 2020, 08:42:25 AM